The synthetic cytokine (Synthokine) SC-55494 is a high-affinity interleukin-3 (11-3) receptor ligand that stimulates greater in vitro multilineage hematopoietic activity than native IL-3, while inducing no significant increase in inflammatory activity relative t o native IL-3. The aim of this study was t o investigate the in vivo hematopoietic response of rhesus monkeys receiving Synthokine after radiation-induced marrow aplasia. Administration schedule and dose of Synthokine were evaluated. All animals were total-body irradiated (TBI) with 700 cGy 8oCo gamma radiation on day 0. Beginning on day 1, cohorts of animals (n = 5) received Synthokine subcutaneously (SC) twice daily with 25 pglkgld or 100 p g l kg/d for 23 days or 100 pglkgld for 14 days. Control animals (n = 9) received human serum albumin SC once daily at 15 pglkgld for 23 days. Complete blood counts were monitored for 60 days postirradiation and the durations of neutropenia (NEUT; absolute neutrophil count IANCI <500/pL) and thrombocytopenia (THROM; platelet count <2O,OOO/pL)
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were assessed. Synthokine significantly ( P < .05) reduced the duration of THROM versus the HSA-treated animals regardless of dose or protocol length. The most striking reduction was obtained in the animals receiving 100 pglkgld for I NTERLEUKIN-3 (IL-3) or multi-colony-stimulating factor (CSF) is a pivotal T-cell-derived cytokine in the stimulation of hematopoiesis. In vitro studies have shown that IL-3 stimulated the proliferation of early multipotential progenitors as well as the growth and differentiation of lineage-restricted colony-forming cells."8 Thus, IL-3 has been reported to stimulate both megakaryocyte progenitor cells and megakaryocytes. Variable responses to native IL-3 in normal monkeys predicted an equivocal response in preclinical and clinical evaluations in situations of marrow failure syndromes and radiation or chemotherapy-induced marrow a~lasia.'"~ Gillio et all5 showed that, although IL-3 enhanced myeloid recovery in cyclophosphamide-or 5-fluorouracil (W) -treated nonhuman primates, platelet recovery could not be shown. In contrast, it has been shown that IL-3 enhanced regeneration of platelets and reduced the duration of thrombocytopenia while showing no effect on recovery of neutrophils in a nonhuman primate model of radiation-induced marrow aplasia.I6.l7 Recently, Winton et all8 showed that once daily administration of IL-3 in a nonhuman primate model of hepsulfam-induced pancytopenia had no demonstrable effect on regeneration of platelets or neutrophils. Clinical studies using IL-3 in marrow failure syndromes or after chemotherapy with or without bone marrow transplantation have shown modest but variable activity in accelerating hematopoietic Therefore, despite its therapeutic potential, native IL-3 is characterized by a relatively narrow therapeutic index due to the intrinsic inflammatory activity of this cytokine. The structure activity relationships of IL-3 have been explored to perform rational design of clinically useful derivatives that would enhance the therapeutic index by reducing hematopoietic cytopenia as well as associated t o x i~i t y . *~-~~ The synthetic cytokine, Synthokine (SC-55494), is a high-affinity IL-3 receptor liBlood, Vol 87, No 2 (January 15). 1996: pp 581-591 23 days (THROM = 3.5 W 12.5 days in HSA control animals). Although the duration of NEUT was not significantly altered, the depth of the nadir was significantly lessened in all animal cohorts treated with Synthokine regardless of dose versus schedule length. Bone marrow progenitor cell cultures indicated a beneficial effect of Synthokine on the recovery of granulocyte-macrophage colony-forming units that was significantly higher a t day 24 post-TB1 in both cohorts treated at 25 and 100 pglkgld for 23 days relative t o the control animals. Plasma pharmacokinetic parameters were evaluated in both normal and irradiated animals. Pharmacokinetic analysis performed in irradiated animals after 1 week of treatment suggests an effect of repetitive Synthokine schedule andlor TB1 on distribution andlor elimination of Synthokine. These data show that the Synthokine, SC55494, administered therapeutically post-TBI, significantly enhanced platelet recovery and modulated neutrophil nadir and may be clinically useful in the treatment of the rnyeloablated host. This is a US government work. There are no restrictions on its use.
gand that has shown 10-to 20-fold greater biologic activity than native IL-3 in human hematopoietic cell proliferation and marrow colony-forming unit assays. Synthokine priming of normal human peripheral blood leukocytes only induced a twofold increase in histamine release and sulfidoleukotriene (LTC,) synthesis versus human IL-3. The functional selectivity of Synthokine may be attributed to the greater binding affinity for the (Y subunit of the (YIP IL-3 receptor complex that Synthokine exhibited relative to native 1L-3. 30 The aim of this study was to investigate the therapeutic efficacy of Synthokine on hematopoietic reconstitution in a nonhuman primate model of high-dose, radiation-induced marrow aplasia.
MATERIALS AND METHODS

.4nimals
Domestic-born male rhesus monkeys, Macaca mulatta, with a mean weight 3.9 2 0.2 kg, were housed in individual stainless steel 
Irradiation
Monkeys placed in an Lucite restraining chair, after a prehabituation period, were bilaterally, total-body irradiated (TBI) with cobalt-60 gamma radiation at the AFRRI Cobalt-60 Facility to a total midline dose of 700 cGy at a dose rate of 40 cGy/min. Dosimetry was performed using a paired 0.5-mL tissue equivalent ionization chamber, whose calibration was traceable to the National Institute of Standards and Technology.
Recombinant Cytokines
Synthokine, SC-55494, is an IL-3 receptor agonist consisting of 1 12 amino acids. This Escherichia coli-derived protein has 21 amino acids deleted from the N-and C-terminal regions, in addition to 27 amino acid position changes relative to native IL-3.3" The Synthokine or the control protein (human serum albumin [HSA]; Miles Inc, Cutter Biological. Elkhart, IN) was administered as a l-mL bolus subcutaneous (SC) injection.
Radiation Study Design
The animals were randomly assigned to one of four treatment groups composed of a minimum of five animals. Each animal was irradiated on day 0. On day 1, groups of animals received Synthokine 
Pharmacokinetic Study Design
Normal rhesus monkeys (n = 2/group) received 25 pgkg intravenous (IV) bolus doses of either Synthokine or native human IL-3 via a spahenous or cephalic vein, and plasma samples were collected at intervals over a S-hour time frame. A second pharmacokinetic study was performed on animals in the therapeutic study before (day -6) and day 7 postirradiation. These animals (n = 2) received 25 pglkg, SC bolus doses of Synthokine, and plasma samples were collected at intervals over an 8-hour time frame.
Clinical Support
An antibiotic regimen was initiated prophylactically when the white blood cell count (WBC) was less than I,M)O/pL and continued daily until the WBC was greater than 1,000lpL for 3 consecutive days. Gentamicin (Lyphomed, Deerfield, IL; 10 mg/d, SC, QD) and rocephin (Roche, Nutley, NJ; 250 mg/d, SC, QD) were administered. Fresh, irradiated (1,500 cGy '"CO gamma radiation) whole blood (approximately 30 mL/transfusion) from a random donor pool (monkeys of > 10 kg body weight) was administered when the PLT count was less than 20,00O/pL and the hematocrit was less than 18%. Transfusions and antibiotics were required to ensure 100% survival in HSA-treated animals (unpublished results).
Hemutologic Evaluations
Peripheral blood. Peripheral blood was obtained from the saphenous vein to assay complete blood (Model S Plus 11; Coulter Electronics, Hialeah, FL) and differential counts (Wright-Giemsa Stain; Ames Automated Slide Stainer, Elkhart, IN). Baseline levels (BL) were obtained before irradiation. These parameters were monitored for 60 days after irradiation and the durations of neutropenia (absolute neutrophil count [ANC] <500/pL) and thrombocytopenia (platelet [PLT] count <20,00O/pL) were assessed. Whole blood transfusions could have possibly altered the ANC and PLT count; therefore, when determining the durations of neutropenia and thrombocytopenia, ANC and PLT counts had to be maintained for 3 consecutive days above threshold levels after the first increase for a true recovery to be noted.
Bone marrow. Approximately 2 mL of bone marrow was aspirated from the humerus and/or iliac crest of anesthetized primates (ketamine, 10 mgikg administered intramuscularly with a 2 I -guage needle in 0.3 mL volume) into preservative-free heparinized syringes. Low-density (<1.077 g/mL) mononuclear cells (MNCs) were separated using Histopaque (Sigma, St Louis, MO) and resuspended in Iscove's modified Dulbecco's medium (IMDM; GIBCO, Grand Island, NY). The clonogenicity of bone marrow progenitor cells was assayed in a short-term culture assay. Culture medium contained 0.9% methylcellulose (Methocult H4230; Stem Cell Tech, Vancouver, British Columbia, Canada) in IMDM with 30% fetal calf serum (Hyclone Laboratories, Logan, UT). In addition, a combination of recombinant human cytokines (granulocyte colony-stimulating fdctor [G-CSF] at S ng/mL; Amgen, Thousand Oaks, CA), mast cell growth factor (MGF; SO ng/mL; Immunex Corp. Seattle, WA), eythropoietin (EPO; 2 UlmL; Behringwerke, Marburg, Germany), 1L-3 (20 ng/mL), granulocyte-macrophage colony-stimulating factor (GM-CSF; S ng/mL), and IL-6 (40 nglmL; Sandoz Pharmaceuticals, East Hanover, NJ), and transferrin ( I O pg/mL; Sigma) were added. MNCs were cultured at a plating density of 5 X IO4 cells/mL (days 0,24, and 46 postirradiation) or I X 10' cells/mL (day 16 postirradiation). Cells were incubated for I O days at 37°C with 5 % COz in air in a fully humidified incubator. Granulocyte-macrophage colonyforming unit (GM-CFU)-and burst-forming unit-erythroid (BFUe)-derived colonies (>50 cells) were expressed as the number of CFU/ 10' MNCs.
Pharmacokinetic Analysis
Affinity-purified goat anti-Synthokine antibody and affinity-purified goat antinative human IL-3 antibody were used in sandwich enzyme-linked immunosorbent assays (ELISAs) to determine Synthokine and native human IL-3 plasma levels. Synthokine or native human IL-3 in plasma was bound in microtiter plate wells precoated with the appropriate goat antibody. The plates were washed, incubated with additional goat antibody conjugated with peroxidase, washed again, and allowed to react with peroxidase substrate and the optical denisty (OD) of the resulting peroxidase product was determined. The plasma determinations were performed using nonvalidated assays with standard curve range lower limits of 1 ng/mL.
Detection of Rhesus Monkey-nti-Synthokine Ig
Antibody titers in plasma samples from Rhesus monkeys dosed with 100 pgkg BID Synthokine were determined by capture ELISA. Samples were tested from days 0; 6, 7, 8, or 9; 13 or 14; 20; and 29,30, or 3 1. Ninety-six-well microtiter platers (Dynatech-Immuion 11, Chantilly, VA) were coated with goat-anti-Synthokine affinitypurified polyclonal antibody. Each well received 150 pL of 100 mmoVL NaHCO, (Fisher Scientific, Pittsburgh, PA), pH 8.2, containing 5 pg/mL goat-anti-Synthokine polyclonal antibody. Plates (Ke~NminatNon) AUC.
were incubated overnight at room temperature in a chamber maintaining 100% humidity. The following morning, wells were emptied and remaining reactive binding sites on the plastic surface of each were well blocked for 1 to 1. A second set of duplicate wells received 150 pL of dilution buffer containing 1 pg/mL Synthokine. Plates were incubated for 2.5 hours in a humidified chamber at 37°C. Wells were emptied and each well was washed four times with wash buffer. Dilutions of plasma samples were then added to their respective plates. Rows A through G of each plate received 150 pL of dilution buffer. Row H received 200 pL of plasma diluted 1: 100. Fifty microliters was removed from row H and titered 1:4 through row A in a serial fashion to cover a dilution range from 1:100 to 1:1,638,400. Plates were incubated for 1.5 hours in a humidified chamber at 37°C. Plates were emptied and each well was washed four times with wash buffer. Each well received 150 pL of dilution buffer containing 0.1 pg/mL of peroxidase-conjugated goat-anti-rhesus monkey Ig (Nordic Immunologicals, Capistrano Beach, CA). Plates were incubated for 1.5 to 2 hours at 37°C in a humidified chamber. Plates were emptied and each well was washed four times with wash buffer. Each well received 150 pL of TMB peroxidase substrate (Kirkegaard and Perry, Gaithersburg, MD). Plates were developed at room temperature for 10 minutes and read on an ELISA reader (Titertek; ICN Medical, Costa Mesa, CA) at a test wavelength of 650 nmol/L. Plasma antibody titers were calculated for each sample after subtracting the average OD of duplicate wells receiving rhG-CSF plus plasma from the corresponding average OD of duplicate wells receiving Synthokine plus plasma.
Statistical Analysis
The Normal Scores Test was used to make painvise comparisons of the durations of neutropenia and thrombocytopenia. The test was performed using the software package StatXact (Cytel Software Cop, Cambridge, MA). The Mann-Whitney test was used to evaluate the statistical significance between the nadirs. Bone marrowderived clonogenic activities were analyzed by two methods. Comparison of treatment days post-TB1 to a historical baseline were made as a one-sided randomization t-test and a Bonferroni correction factor of 3 was applied to the P values. The comparison of treated groups versus the time-matched, HSA-treated controls were made
RESULTS
Pharmacokinetics of Synthokine in Normal and Irradiated Monkeys
The results indicated similar pharmacokinetic behavior of Synthokine and native IL-3 after IV injection in the rhesus monkey. The half-life was somewhat shorter (TlI2 = 46.1 minutes v 52.5 minutes), but clearance was slower (4.38 mLl midkg v 5.51 mL/min/kg) for Synthokine compared with native IL-3 (Table 1) .
The bioavailability of Synthokine administered SC in the rhesus monkey in this study cannot be calculated directly because the IV and SC doses were administered to separate groups of monkeys. However, comparison of the IV and SC area under the curve (AUC) values indicates a bioavailability of approximately 100%. Synthokine was detected in the plasma collected from 0.25 to 8.0 hours after SC administration of 25 pglkgldose. The average CMAX in normal monkeys was 25.7 ng/mL, whereas the average TMAX and AUC were 1.3 hour and 106 ng/mL/h (0-to 8-hour period; Table 1 ).
Plasma concentrations after SC administration to irradiated animals (measured at day 7 post-TBI) were between two and three times higher than values determined in the same animals before irradiation ( Table 2 ). The average CMAX on day 7 after TB1 was 55.9 ng/mL, whereas the average TMAX and AUC were 1 .S hour and 285 ng/mL/h, respectively, relative to values for CMAX of 25.7 ng/mL, TMAX of 1.3 hour, and AUC of 106 ng/mL/h for Synthokine administered to animals before radiation exposure.
ELISA Determination of Rhesus Monkey-Anti-Synthokine Plasma Ig
There were no antibody titers to Synthokine detected at any evaluated time points post-TB1 in the animals receiving 100 pg/kg/d for either the 14-day or 23-day schedule.
Modulation of Thrombocytopenia
Thrombocytopenia (PLT <2O,OOO/pL) was evident in HSA-treated control animals for an average of 12.5 days (days 10 * Average values for 2 monkeys. Monkey received TB1 with @'CO gamma radiation to a total midline dose of 700 cGy on day 0. Each animal received a 25 pglkg SC dose of Synthokine on day -6 (before TBI) and day +7 (after TBI). Each animal also received 25 pg/kg SC doses of Synthokine twice daily on days 1 through 6.
For Table 3 ). Administration of Synthokine at 25 or 100 pgl kg/d for 23 consecutive days post-TB1 significantly reduced the duration of thrombocytopenia relative to HSA-treated controls to 7.4 days (P = .019 ) and 3.5 days (P = .OOl), respectively ( Fig 1A and Table 3 ), whereas the 100 p&g/ d dose administered for only 14 consecutive days post-TB1 reduced the thrombocytopenic period to 6.2 days ( P = .003; Fig 1B and Table 3 ). The administration of Synthokine for 23 days at the 100 pg/kg/d dosage produced a reduction in the duration of thrombocytopenia that was significantly greater than both the 14-day protocol at the same dose (3.5 v 6.2 days, P = .048) and the same 23-day protocol at the lower dosage of 25 pg/kg/d (3.5 v 7.4 days, P = ,028). There was no significant (P = .187) difference in the duration of thrombocytopenia when Synthokine was administered for 14 days at 100 pg/kg/d (6.2 days) versus 25 pgkgld dose for 23 days (7.4 days). The administration of Synthokine, regardless of treatment protocol, accelerated platelet recovery, with preirradiation baseline levels being attained within approximately 28 days after exposure. In contrast, HSA-treated controls required approximately 40 days to attain baseline levels (Fig 1A) . The platelet nadir was significantly decreased relative to that of the HSA-treated controls only in the cohort of animals treated with Synthokine at 100 pg/kg/d for 23 consecutive days.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Monkeys whole body irradiated with ' %o gamma radiation were treated with control protein (HSA) or Synthokine according to protocol. Neutropenia is defined as an ANC less than 5001bL. Thrombocytopenia is defined as a platelet count of less than 20,OOOlpL.
x Statistically significant difference from the HSA-treated controls. t Statistically significant difference from the 100 pglkgld, 14-day protocol and the 25 pglkgld, 23-day protocol.
Modulation of Red Blood Cells and Transfusion Requirements
Synthokine administration at 100 pgkgld for 23 days in- Monkeys whole body irradiated with mCo gamma radiation were treated with control protein (HSA) or Synthokine according to protocol. Animals received transfusion of fresh, irradiated (1,500 cGy %o) whole blood (approximately 30 mUtransfusion) from a random donor pool when the platelet count was less than 20,OOO/hL and the hematocrit was less than 18%. treated for 14 or 23 consecutive days received an average of less than one transfusion per animal ( Table 4) .
Modulation of Neutropenia
Although the duration of neutropenia (ANC <500/pL) was not significantly altered with Synthokine treatment ( P > SO), the depth of neutrophil nadir was lessened in all cohorts of animals treated with Synthokine relative to the HSA-treated control animals ( Fig 3A and B and Table 3 (Fig 3A, B) and did not modify the antibiotic requirements during the neutropenic period.
Effect of Synthokine Administration on Bone Marrow Progenitor Cell Recovery
The bone marrow-derived clonogenic activities for BFUe and GM-CFU were signifcantly ( P < .05) depressed through day 46 post-TB1 in the HSA-treated controls (Fig 4A and  B) . In contrast, the BFUe and GM-CFU values for all Synthokine treatment protocols recovered to BL levels no later than day 46 post-TB1 (Fig 4A and B) . The 23-day administration of synthokine at either 25 or 100 yg/kg/d significantly increased ( P 5 .OS) the GM-CFU activity versus the timematched, HSA-treated controls by day 24 post-TB1 (Fig 4B) . The animals receiving the shortened Synthokine protocol (14 days) also displayed increased GM-CFU activity at day 24 post-TB1 versus the time-matched controls ( P = .06); however, a significant increase ( P = .03) was not noted until day 46 post-TB1 (Fig 4B) . The BFUe activity in all three Synthokine treatment groups was significantly ( P < .OS) increased above the time-matched, HSA-treated controls at day 46 post-TB1 (Fig 4A) .
DISCUSSION
Hematopoietic growth factors such as GM-CSF, IL-3, IL-6, IL-11, leukemia inhibitory factor (LIF), and megakaryo- MNCs.
Dose Synthokine (pg/kg)
cyte growth and development factor (MGDF) or thrombopoietin (Tpo) have been shown to stimulate megakaryocyte differentiation in vitro and enhance platelet production in preclinical models of normal and radiation or drug-induced CSF and GM-CSF have shown therapeutic efficacy in accelerating production of n e~t r o p h i l s .~.~~ Thrombocytopoietic efficacy in clinical situations of marrow failure has not been realized for GM-CSF, whereas IL-3 and L 6 efficacy has been questionable due to their low therapeutic indices and IL-I 1 is currently in clinical The demonstrated in vitro efficacy of IL-3 as a growth factor for stimulation of multipotent and committed myeloid progenitors suggested that it may play a major role as a primer by increasing the action of more lineage-restricted cytokines such as G-CSF, GM-CSF, L-6, and IL-I 1. Such efficacy has recently been shown in preclinical models of radiation or drug-induced marrow apasia for the combination of IL-3 with GM-CSF or L -6 and forecast the efficacy of the IL-3/GM-CSF fusion protein, PIXY321.'6"8,77,78 In addition, L -3 has been shown to promote survival of primitive murine and human hematopoietic progenitor ~e l l s .~~-~* Brandt et a1" recently showed that addition of IL-3 to cultures of highly enriched human committed progenitor cells delayed the appearance of morphologic changes and DNA fragmentation patterns associated with apoptosis. The demonstrated efficacy of L 3 in promoting increased proliferation as well as survival of hematopoietic progenitor cells warranted further analysis of the growth factor with regard marrow ap~asia.i.14.16-1X.31-63 The lineage-specific cytokines Gto structure function relationships and improving its clinical therapeutic index.
The synthetic cytokine, Synthokine, is a high-affinity IL-3 receptor ligand that has shown greater in vitro multilineage growth factor activity than native L -3 while inducing no significant increase of inflammatory activity. The enhanced binding to the CY subunit has been implicated as a key determinant of Synthokine's increased in vitro biologic activity. The purpose of this study was to evaluate the efficacy of Synthokine in decreasing the time to recovery from neutropenia and thrombocytopenia in a nonhuman primate model of radiation-induced marrow aplasia. The protocols evaluated two doses of Synthokine (25 v 100 pg/kg/d) administered over 23 consecutive days postirradiation, as well as one dose (100 pg/kg/d) of Synthokine administered over both 14-day and 23-day schedules relative to HSA-treated control animals.
We showed that Synthokine was able to ameliorate the clinically significant, radiation-induced nadirs in ANC and PLT, as well as to significantly decrease the duration of thrombocytopenia without significant toxicity or morbidity relative to HSA-treated controls. Neither the dose of Synthokine nor the protocol schedule affected the duration of neutropenia or recovery of ANC to baseline, preirradiation values. This occurs despite the fact that Synthokine administration accelerated the postirradiation recovery of marrowderived GM-CFU progenitors relative to the control response. This apparent discrepancy between clonogenic data and peripheral blood leukocyte counts could be explained
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by the fact that the enhanced bone marrow GM-CFU recovery was observed from day 24 post-TBI. It would take approximately 10 days for these progenitors to differentiate into mature leukocytes. At that time (day 30 to 3 1 postirradiation), the ANC appeared to be greater in the Synthokinetreated animals (100 pg/kg/d for 23 days) relative to the HSA group. IL-3-stimulated proliferation of primate and human marrow progenitors has been shown with administration schedules as short as 7 consecutive days, whereas longer treatment schedules were required to stimulate variable levels of circulating neutrophils and platelet^.^.'^.^^.'^ These results suggested that the increase in mature cell lineages is dependent on the interaction of IL-3-primed progenitors with lineage-specific cytokine~.'~In two previous studies, we were unable to show the efficacy of native IL-3 in reducing neutropenic duration or recovery of ANC to preirradiation level^.^^,^' In contrast, Gillio et a l l 5 reported that IL-3 reduced both neutrophil nadir and duration of neutropenia in cyclophosphamide-and 5-FU-treated cynomolgus primates, whereas no increase in platelet production could be shown. Winton et a1,I8 using hepsulfam-induced pancytopenia in rhesus primates, could not show therapeutic efficacy of native IL-3 for restoring platelets or neutrophils. However, the administration protocol (a single daily, SC injection) may account for the ineffectiveness of the native IL-3 in this model." It is of interest that our pharmacokinetic analysis of Synthokine versus native IL-3 showed similar values and suggests a BID protocol for effective SC administration. It is also of interest that plasma concentrations of Synthokine were between two to three times higher at day 7 after TB1 compared with their preirradiation values. These results indicate an effect of repetitive Synthokine administration (7 consecutive days) and/or of TB1 on distribution and/or elimination of Synthokine.
Administration of Synthokine significantly enhanced the recovery of PLT to preirradiation levels and reduced the duration of thrombocytopenia at both doses and schedules used, as well as reduced the nadir of PLT at the highest dose administered over the 23-day schedule compared with the HSA-treated controls. We previously showed the efficacy of native IL-3 in accelerating PLT recovery and reducing the thrombocytopenic p e r i~d .~~,~' Two doses (25 and 100 pg/kg/ d) of Synthokine were evaluated in this model because of noted modest hematopoietic activity of native IL-3 and Synthokine in rhesus primate bone marrow-derived cell cultures (attributable to 81% and 64% respective homology to rhesus IL-3; unpublished results). van Gils et alX5 have also shown that native human IL-3 does not bind efficiently to rhesus marrow-derived target cells. The 100 pg/kg/d dose reduced the duration of thrombocytopenia to 3.5 days versus 7.4 days for the 25 pg/kg/d dose relative to 12.5 days for the HSAtreated controls treated on the 23-day injection schedule.
These data showed that Synthokine significantly enhanced platelet recovery and modulated neutrophil nadir after radiation-induced marrow aplasia and suggests that it may be clinically useful in the treatment of the myeloablated host. The 14-day treatment schedule at 100 pg/kg/d was not significantly more efficient than a 23-day therapeutic schedule at 25 pg/kg/d in terms of both the duration of thrombocytopenia (7.4 days in the 25 pg/kg/d for 23-day group v 6.2 days in the 100 pg/kg/d for 14-day group) and bone marrow clonogenic activity. According to our data, the duration of treatment (especially beyond day 14 post-TBI) could be of critical importance to sustain recovery. We can hypothesize that, 2 weeks postirradiation, the compartment of radiationdepleted hematopoietic progenitors such as granulocyte, erythroid, macrophage, monocyte CFU, GM-CFU, and BFUe entered an active period of self-renewal and differentiation to replenish the peripheral blood mature cell compartment. The committed precursors should therefore be in a strong cytokine-dependent state. Any interruption of the treatment might induce a phenomenon of deprivation, similar to that observed in vitro with bone marrow-derived cells, lL-3-dependent cell line cultures, or hematopoietic progenitor cells when removing IL-3 or kit-ligand, which could interfere with hematopoietic r e c o~e r y .~"~'~'~~~" This consideration has to be taken into account for the design of future clinical trials. These data also suggest that combined protocols of Synthokine with lineage-restricted cytokines such as G-CSF or GM-CSF would provide the desired effect of enhancing hematopoietic production of both platelets and neutrophils. The demonstrated therapeutic efficacy of combined, concurrent native human IL-3 and GM-CSF as well as the IL-3/GM-CSF fusion protein PIXY321 in a similar model of radiation-induced marrow aplasia would forecast efficacy for Synthokine and G-CSF.'h,7x For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
